FMEA.BE : Summary for FRESENIUS MD.CARE ADR 1/2 - Yahoo Finance

U.S. Markets closed

FRESENIUS MD.CARE ADR 1/2 (FMEA.BE)


Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
37.93-0.19 (-0.49%)
At close: 8:00AM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close38.12
Open37.93
Bid37.97 x
Ask38.21 x
Day's Range37.93 - 37.93
52 Week Range37.93 - 38.46
Volume0
Avg. Volume0
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters21 days ago

    Dialysis provider FMC settles with U.S. veterans department

    Dialysis provider Fresenius Medical Care (FMC) settled a dispute with the United States Departments of Veterans Affairs and Justice over outstanding payments and expects to book a net income gain of 45 to 50 million euros ($48.2-$53.5 million) as a result. The settlement, which covers healthcare services provided to veterans from January 2009 to February 2011, will also lead to an increase in FMC's 2017 revenue by about 100 million euros, the German company added.

  • Reuters27 days ago

    U.S. court issues injunction on assistance for dialysis patients

    A U.S. court has issued a preliminary injunction on a new federal rule that dialysis providers have said would prevent patients from using charitable assistance to buy private health insurance, Fresenius Medical Care (FMC) said on Thursday. The decision upholds a temporary hold on the rule and is a victory for dialysis providers FMC, DaVita Inc and U.S. Renal Care Inc, which had filed a lawsuit to block the rule. "The preliminary injunction is indefinite in duration and therefore will remain in effect as long as the court does not change it," FMC said.

  • Zacks Small Cap Researchlast month

    CTSO: Poised For Strong 2017. Fresenius Deal A Win-Win-Win

    CytoSorbents (CTSO) has had a busy last couple of months leading up to the annual JP Morgan, Biotech Showcase and Medtech Showcase conferences which were held earlier this week in San Francisco and where management took some time to talk to us.  Just prior to the company’s presentation at the Biotech Showcase they announced an expanded agreement with Fresenius and preannounced expected Q4 and FY2016 product sales. Per the January 10th preannouncement, CTSO expects Q4 product sales of ~$2.6M, implying sequential and yoy growth of approximately 21% and 74%, respectively, and marking the sixth straight quarter of record product sales.  Product sales of $2.6M is also almost 16% higher than what we had forecast ($2.2M).